Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $53.3B — +13.9% growth in a single year.
What Moves the Stock
01Same-store sales (SSS) growth rates - driven by customer traffic, ticket size, and product mix shift toward higher-margin categories
02Store expansion pace and new store productivity - net openings targeting 240-260 annually with focus on underserved regions in North/Northeast Brazil
03EBITDA margin trajectory - investors focus on 8-9% normalized margin potential versus current 7-8% range through scale and operational efficiency
04Brazilian Real exchange rate volatility - impacts valuation multiples for foreign investors and affects imported pharmaceutical costs
05Competitive dynamics with Pague Menos (PGMN3) and regional chains - market share gains in key metropolitan areas
06Prescription pharmaceuticals (estimated 65-70% of revenue) - branded and generic drugs dispensed through retail stores
07Over-the-counter medications and health products (estimated 15-20%) - vitamins, supplements, personal care items
growth - The stock attracts growth investors seeking exposure to Brazilian middle-class consumption trends and healthcare sector structural…
Brazilian SELIC rate movements significantly impact the business through multiple channels.
Watch on earnings: Brazilian SELIC interest rate (Banco Central do Brasil policy rate) - affects consumer credit, working capital costs, and valuation multiples, Brazilian Real (BRL) exchange rate versus USD - impacts foreign investor returns and imported pharmaceutical input costs, Brazil retail sales volume index - leading indicator for consumer spending capacity and discretionary health product demand.
One Sentence Summary:
Raia Drogasil: the story is balanced — same-store sales (sss) growth rates - driven by customer traffic, ticket size, and product mix shift toward higher-margin categories.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
